Talk:Factor X deficiency

Kimwestclark (talk) 19:36, 13 February 2020 (UTC)

Some proposed changes
This article needs the following statement corrected: “There are several treatments available for bleeding due to factor X deficiency, however a specific FX concentrate is not available (2009).” The reference for this statement is no longer up-to-date regarding current treatment options, and as of September 2018, COAGADEX® (Coagulation Factor X (Human)) is approved by the FDA for the treatment of adults and children with hereditary factor X deficiency. Please see The Genetic and Rare Diseases Information Center (GARD) website: https://rarediseases.info.nih.gov/diseases/6404/factor-x-deficiency

Kimwestclark (talk) 19:37, 13 February 2020 (UTC)

Reply 13-FEB-2020
Regards, Spintendo  21:52, 13 February 2020 (UTC)
 * The text in question states that "a specific FX concentrate is not available". The COI editor proposes that CoagaDex meets the definition of a specific FX concentrate. However, the reference supplied with the request does not state that this agent is an FX concentrate. Please provide references which use and verify the article's terminology.
 * Meanwhile, until this clarification is provided, the article's statement about a specific concentrate not being available has been reworded to reinforce the claim that the statement was applicable as of 2009. That way, the statement is true even if there were later developments.

Reply 27-FEB-2020
This response is to address the Clarification Request regarding the quote "a specific FX concentrate is not available", and the need for a reference which uses the article's terminology and describes Coagadex as an FX concentrate. Please see https://www.drugs.com/pro/coagadex.html, which addresses the approved indication for Coagadex, and specifically the section located at https://www.drugs.com/pro/coagadex.html#s-34089-3 which refers to Coagadex as a 'concentrate of human coagulation Factor X'.

Regards,

Kimwestclark (talk) 20:14, 27 February 2020 (UTC)